Euroapi plans initiatives to support production of APIs in France and Europe

Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026

Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio

Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio

Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData

Pfizer is likely to show GSK significant competition

InnoCan submits new patent applications for advanced pain relief technology

The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution

Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule

UTD2 is the world's first oral epothilone microtubule inhibitor

Astellas submits new drug application for Zolbetuximab in Japan

Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers

Novartis to acquire Chinook Therapeutics for US$ 3.2 bn

Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease

Milla receives first cycle FDA approval for Dexmedetomidine Hydrochloride Injection

Ecolab expands biologics resin manufacturing facility in Pennsylvania

New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.

Lonza signs VPPA for solar power supply with Ignis

Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.